Pharmacokinetic Drug Evaluation of Mepolizumab for the Treatment of Severe Asthma Associated With Persistent Eosinophilic Inflammation in Adults
Introduction: Mepolizumab is a humanized monoclonal antibody that binds to and inactivates IL-5. It is available as a subcutaneous preparation. The practical application of mepolizumab is as an add-on therapy in the treatment of severe eosinophilic asthma. Areas covered: This article was created from a comprehensive literature search with information taken from meta-analyses, systematic reviews, and clinical trials of adults. The articles that have been selected evaluate the use of mepolizumab and its role in eosinophilic asthma. Expert opinion: Mepolizumab is significantly more effective than placebo in reducing exacerbations and need for systemic corticosteroids in severe eosinophilic asthma. There is a lack of head to head studies comparing mepolizumab to other monoclonal anti-IL-5 inhibitors in severe eosinophilic asthma. Post marketing surveillance revealed risk of anaphylaxis that is below 1%.
Kallur, Lakshmi; Gonzalez-Estrada, Alexei; Eidelman, Frank; and Dimov, Ves. 2017. Pharmacokinetic Drug Evaluation of Mepolizumab for the Treatment of Severe Asthma Associated With Persistent Eosinophilic Inflammation in Adults. Expert Opinion on Drug Metabolism and Toxicology. Vol.13(12). 1275-1280. https://doi.org/10.1080/17425255.2017.1406919 PMID: 29157020 ISSN: 1742-5255